Loading...
•
Mar 31, 2022
Capricor Q1 2022 Earnings Report
Capricor reported results for the first quarter of 2022 and provided a corporate update.
Key Takeaways
Capricor Therapeutics reported a net loss of $7.8 million, or $0.32 per share, for the first quarter of 2022. The company's cash and cash equivalents totaled approximately $58.3 million as of March 31, 2022, bolstered by a $30 million upfront payment from Nippon Shinyaku for the commercialization and distribution of CAP-1002.
Secured partnership with Nippon Shinyaku for CAP-1002 commercialization in the US, receiving $30 million upfront.
Published positive Phase 2 results in The Lancet, validating CAP-1002's efficacy in treating DMD.
Advanced Phase 3 HOPE-3 trial preparations, with patient enrollment expected to begin in Q2 2022.
Expanded pipeline using engineered exosomes, investing in scaled-up manufacturing.
Forward Guidance
Capricor expects its available cash and cash equivalents will be sufficient to cover anticipated expenses and capital requirements for at least two years.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...